Info
As a scientist, I make evidence-based decisions. As an entrepreneur, I am a…
Artikel von Dr. Petra Jantzer
-
It’s Time to Rewrite the Rulebook on Careers
It’s Time to Rewrite the Rulebook on Careers
It’s Time to Rewrite the Rulebook on Careers Have you ever been part of something that aligns with your core beliefs in…
7 Kommentare
Aktivitäten
9387 Follower:innen
-
Dr. Petra Jantzer hat dies geteiltI am excited to share that Accenture has been recognized by Ethisphere as one of the World’s Most Ethical Companies for the 19th consecutive year. This recognition reflects sustained discipline in how a global organization operates responsibly—especially as technology, data, and AI become more central to value creation. For clients and partners, trust is built through execution—through ethical leadership applied consistently in how work gets done. In Life Sciences, that consistency matters deeply, shaping how data is governed, how technology is applied, and how decisions ultimately affect patient outcomes. I’m grateful to work alongside colleagues who consistently bring these values to life—something I value as the work continues to evolve. #WorldsMostEthicalCompanies #Accenture
-
Dr. Petra Jantzer hat dies geteiltThe real value of AI doesn’t come from technology alone; it comes from advancing people and technology together. For life sciences leaders, that’s where the talent conversation is shifting—from scale to substance. The real question is whether our operating models help people create value alongside AI, or quietly get in the way. In my work with R&D and commercial teams, I see Gen AI pilots move fast, but impact stall when work isn’t redesigned—when roles, skills, and decision rights haven’t kept pace with the science. That’s why Accenture’s Talent Reinventors: Delivering value with and for people in the age of AI research resonates with me. Real value shows up when people and technology advance together—and that’s how investment turns into impact. For regulated, science‑led organizations, this is a leadership issue. Talent strategy is now a core value lever, not an HR adjacency. Read more: accntu.re/4dLfwwg #LifeSciences #TalentStrategy #AI
-
Dr. Petra Jantzer hat dies geteiltThe question for life sciences organizations today isn’t whether to adopt AI. It’s how to do it without putting regulatory credibility at risk. That’s why I’m excited about Accenture’s new investment and strategic partnership with Iridius. Mike Kropp has built an AI infrastructure where compliance is embedded into enterprise workflows by design—creating a real foundation for scaling in regulated environments. Combined with Accenture’s delivery scale and deep life sciences expertise, this partnership will help our clients move from AI experimentation to enterprise‑wide, audit‑ready transformation. This means faster clinical timelines, less manual compliance work, and therapies reaching patients sooner. This is what AI for life sciences should look like. Read more: https://lnkd.in/eMegbFzU #LifeSciences #AI #Compliance #AccentureVentures #Iridius
-
Dr. Petra Jantzer hat dies geteiltFor life sciences leaders, the focus with AI is increasingly practical: how to move from localized progress to enterprise‑level impact. Accenture’s latest report captures this shift well. As the executive summary notes, “With AI pilots everywhere, leaders now face the harder question: how to turn pockets of impact into enterprise‑wide value.” Three implications stand out for life sciences: - Value scales after foundations are in place — connected data, governed workflows, and clear decision rights across R&D, manufacturing, and commercial. - AI can’t reinforce what isn’t explicit. Tacit decisions and informal handoffs limit consistency and scale. - Readiness, not ambition, is the differentiator. Read this report by Manish Sharma and Senthil (Sen) Ramani for more: accntu.re/4sEmLtR #ArtificialIntelligence #Leadership #LifeSciences #DigitalTransformation
-
Dr. Petra Jantzer hat dies geteiltThis is where reinvention becomes tangible. When biopharma leaders treat CMC and manufacturing as design levers — not downstream constraints — the system starts to behave differently. Decisions get made with scale, quality, and speed in mind from the outset, rather than reconciled later. That shift is quietly redefining what execution excellence really means in today’s biopharma organizations.Dr. Petra Jantzer hat dies geteiltI’m excited to share our latest Accenture research Reinventing biopharma from lab to line: Fueling smarter, faster and scalable biopharma production with intelligent technologies. Our research shows as pipelines grow more complex and AI accelerates drug discovery, manufacturing and CMC are emerging as biopharma industry’s opportunities for long‑term competitive advantage. We provide a practical playbook for our clients to realize a ‘product lifecycle of the future’ through digital transformation and scaled adoption of intelligent technologies. Biopharma companies embracing intelligent technologies across technical operations are already seeing success, from faster launches to improved cycle times, ultimately driving greater patient impact. See our report to learn more about unlocking the full value of digital and AI in biopharma production: https://lnkd.in/gr6BX8RM Selen Karaca-GriffinDr. Petra JantzerRay PressburgerHagen SpäthBarry HeaveyBrendan H.Brad MichelCarly GuentherCraig Robertson
-
Dr. Petra Jantzer hat dies geteiltR&D careers are no longer ladders; they’re portfolios of skills. This recent BioSpace article by my Accenture colleagues Selen Karaca-Griffin and Kenneth Munie resonates deeply with what I’m seeing across biopharma R&D. AI is accelerating the shift toward skills‑based careers — even in highly regulated environments. What excites me truly is the implication for leaders: If skills are the new currency, then how we design R&D work, teams, and progression must fundamentally change. Are our organizations structured to build the skills that matter most? Read more: https://lnkd.in/eUsBb7-23 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy3 Career Moves R&D Professionals Must Make in a Skills-Based, AI-Driven Economy
-
Dr. Petra Jantzer hat dies geteiltJames, this resonates strongly from a Life Sciences perspective. As AI agents begin to shape a substantial share of work, scale alone won’t differentiate leaders—operating models will. In regulated, patient‑critical environments, direction, guardrails and accountability aren’t constraints; they’re what make co‑intelligence viable at all. What’s truly pivotal is how leading organizations are redesigning scientific, clinical and quality workflows—not just layering agents on top. Where are you seeing the most consequential redesign of work happening first?Dr. Petra Jantzer hat dies geteiltMore than half of working hours are expected to be impacted by #AI agents, creating a significant shift in how work and value are generated. The critical question is how much of that change shows up in measurable growth and performance. Our latest report, The Age of Co‑Intelligence, created in partnership with Wharton, examines how enterprise value is shaped as agentic work scales. It highlights how leadership choices around direction, guardrails and operating models influence where economic impact concentrates. Organizations capturing the greatest returns are moving beyond adoption and actively redesigning how work gets done. Learn more: https://lnkd.in/e_YgbmDP Many thanks to my co‑authors Kenneth Munie, Karalee Close, Selen Karaca-Griffin, Eric Bradlow and The Wharton School for an incredible collaboration.
-
Dr. Petra Jantzer hat dies geteiltThank you to Advance – Gender Equality in Business for this thoughtful post and for continuing to elevate this conversation. AI is a defining moment for women because early engagement shapes what becomes possible. This isn’t about becoming experts overnight — it’s about stepping in, experimenting, and staying close to the change. Confidence isn’t a prerequisite for AI; it’s the result. What makes this moment truly consequential is that digital proficiency compounds. For women, starting now builds agency, influence, and choice over time. I’m truly grateful to be part of a community that’s leaning in early and shaping what comes next — together.Dr. Petra Jantzer hat dies geteiltIf you’ve been hesitating about how — or when — to start using AI, this keynote from our International Women’s Day celebration is the nudge you’ve been waiting for. In “𝐊𝐞𝐞𝐩 𝐨𝐧 𝐒𝐡𝐚𝐩𝐢𝐧𝐠: 𝐖𝐡𝐲 𝐓𝐡𝐢𝐬 𝐃𝐢𝐬𝐫𝐮𝐩𝐭𝐢𝐨𝐧 𝐈𝐬 𝐘𝐨𝐮𝐫 𝐌𝐨𝐦𝐞𝐧𝐭, Dr. Petra Jantzer, Global Life Sciences Lead at Accenture, speaks directly to women navigating today’s transformation. Her core message is clear and empowering: “𝐘𝐨𝐮 𝐝𝐨𝐧’𝐭 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐦𝐚𝐬𝐭𝐞𝐫 𝐀𝐈 𝐛𝐞𝐟𝐨𝐫𝐞 𝐲𝐨𝐮 𝐮𝐬𝐞 𝐢𝐭. 𝐘𝐨𝐮 𝐧𝐞𝐞𝐝 𝐭𝐨 𝐮𝐬𝐞 𝐢𝐭 𝐭𝐨 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐦𝐚𝐬𝐭𝐞𝐫𝐲.” Petra also shares five concrete actions you can take to start shaping your future today and captures the urgency of this moment with one striking insight: 💡 “𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐫𝐨𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 𝐢𝐬 𝐭𝐡𝐞 𝐧𝐞𝐰 𝐜𝐚𝐫𝐞𝐞𝐫 𝐜𝐮𝐫𝐫𝐞𝐧𝐜𝐲 – 𝐢𝐭 𝐜𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐬 𝐟𝐨𝐫 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐢𝐧𝐯𝐞𝐬𝐭 𝐞𝐚𝐫𝐥𝐲. 𝐈𝐭 𝐝𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐞𝐬 𝐭𝐡𝐞 𝐬𝐚𝐯𝐢𝐧𝐠𝐬 𝐨𝐟 𝐭𝐡𝐨𝐬𝐞 𝐰𝐡𝐨 𝐰𝐚𝐢𝐭.” 📺 Watch the recording and then put the insights into actions: https://lnkd.in/emG-F2ig #KeepOnAdvancing #IWD2026
-
Dr. Petra Jantzer hat dies geteiltAI is advancing fast across Life Sciences—but technology alone won’t deliver the outcomes our industry needs. Accenture Research on 𝐓𝐚𝐥𝐞𝐧𝐭 𝐑𝐞𝐢𝐧𝐯𝐞𝐧𝐭𝐨𝐫𝐬: 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐢𝐧𝐠 𝐯𝐚𝐥𝐮𝐞 𝐰𝐢𝐭𝐡 𝐚𝐧𝐝 𝐟𝐨𝐫 𝐩𝐞𝐨𝐩𝐥𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐚𝐠𝐞 𝐨𝐟 𝐀𝐈 reinforces a simple truth we see every day in Pharma and MedTech: in a fast‑changing world, organizations that rethink how they manage talent alongside AI are the ones creating real advantage. For Life Sciences leaders navigating skills scarcity, regulatory complexity, and pressure to scale innovation, the research offers timely perspective on what separates progress from stalled transformation. Read more. accntu.re/40uWuCz
Dr. Petra Jantzer hat einen Beitrag kommentiert
2 Monate
David, the WAsX makes one thing unmistakable: Life Sciences isn’t struggling with talent — it’s struggling with precision skills.
Generalist traits sit in surplus, while scientific, analytical and execution‑level capabilities remain the real scarcity — and that scarcity slows discovery, trials and scale‑up.
What excites me truly is how clearly the data shows this shift: capability architecture now matters more than job architecture.
Dr. Petra Jantzer hat einen Beitrag kommentiert
2 Monate
Herzlichen Glückwunsch lieber Patrick! Viel Spass und Erfolg in und mit Deiner neuen Rolle!
Dr. Petra Jantzer hat einen Beitrag kommentiert
3 Monate
Dear Rahul, I am so sorry and sad about your loss of Mary. I was never lucky enough to meet her but her light shines brightly through your words, and I am deeply moved by the love you shared. I wish you and your children a lot of strength, love and healing. Heartfelt condolences dear Rahul.
Berufserfahrung und Ausbildung
-
Advance – Gender Equality in Business
Gesamte Berufserfahrung von Dr. Petra Jantzer anzeigen
Jobbezeichnung, Beschäftigungsdauer und mehr ansehen.
oder
Bescheinigungen und Zertifikate
Patente
-
T-Zellrezeptor-Expressionskassette
Ausgestellt am EU WO1999052943 A1
Abstract
The invention relates to a method for expressing T cell receptors and vectors that are suitable therefor. The invention also relates to cells that are transfected with vectors and are able to express the desired T cell receptors.Andere Erfinder:innen -
Auszeichnungen/Preise
-
HBA Luminary
Healthcare Businesswomen Association
Luminaries serve as a role model in their company, actively mentor and sponsor others, help advance other women’s careers, and exhibit dedication to the healthcare industry. These luminary leaders have more than 20 years of professional industry experience.
Sprachen
-
German
Muttersprache oder zweisprachig
-
English
Verhandlungssicher
-
French
Gute Kenntnisse